Leriglitazone (MIN-102) is a novel, brain penetrant, orally bioavailable and
selective PPARγ agonist
Second Orphan Drug Designation granted by the FDA for leriglitazone in addition to
X-linked adrenoleukodystrophy (X-ALD)
Potential for seven years of marketing exclusivity in the USA upon approval in the
orphan designation indication
Can't see this document? Click Here
